ISCO (International Stem Cell) ROCE %: -456.79% (As of Mar. 2026)

What is International Stem Cell ROCE %?

International Stem Cell ISCO +4.76% 28 ROCE % is -456.79% as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 28/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. International Stem Cell's annualized ROCE % for the quarter that ended in Mar. 2026 was -456.79%.

International Stem Cell (OTCPK:ISCO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

International Stem Cell ROCE % Related Terms

International Stem Cell ROCE % Historical Data

* Premium members only.

The historical data trend for International Stem Cell's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell ROCE % Chart

International Stem Cell Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-34.53

-33.73

1.51

-12.27

-73.66

International Stem Cell Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-171.83	118.86	60.89	-288.81	-456.79

28GF Score

International Stem Cell Corp ISCO

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

International Stem Cell ROCE % Calculation

International Stem Cell's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-0.267	/	( ( (5.173 - 4.688)	+	(4.819 - 4.579) )	/ 2 )
	=	-0.267	/	( (0.485	+	0.24)	/ 2 )
	=	-0.267	/	0.3625
	=	-73.66 %

International Stem Cell's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-0.74	/	( ( (4.819 - 4.579)	+	(5.133 - 5.049) )	/ 2 )
	=	-0.74	/	( ( 0.24	+	0.084 )	/ 2 )
	=	-0.74	/	0.162
	=	-456.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -456.79% mean?

International Stem Cell (ISCO) has a ROCE % of -456.79% as of Mar. 2026.

Is International Stem Cell's ROCE % too high?

International Stem Cell's current ROCE % is -456.79%. Overall, International Stem Cell has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does International Stem Cell's ROCE % compare to ONCO and VRAX?

International Stem Cell's ROCE % of -456.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. International Stem Cell's current ROCE % is -456.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is International Stem Cell stock overvalued right now?

Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37% above its estimated fair value. The current ROCE % is -456.79%. International Stem Cell's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For International Stem Cell (ISCO), the current ROCE % is -456.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 37% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

ROCE %: -456.79%
GF Value™: $0.13 vs. price of $0.18 (37% above fair value)
GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Industry Healthcare Biotechnology

Comparable Companies ONCO VRAX LYRA ABPO BPTH ADAPY ZVSA CLSDQ BZYR ATXI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

28GF Score

Get the complete analysis for ISCO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18

Price

$0.13

GF Value

View ISCO Analysis

See ROCE % data for all stocks →